Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken with, as the focus had shifted to the rate of improvement in all-cause mortality which showed a directional improvement at 1-year (12.6% vs. 15.2%) but was not powered to show superiority. As a result of these data and our own market due diligence, we remain constructive on the tricuspid valve opportunity overall, and are increasingly encouraged by the opportunity for both EVOQUE and the broader TMTT portfolio for Edwards."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $69.37 yesterday.

You May Also Be Interested In

• 22nd Century Group files prospectus for warrant share resale
• MicroVision applies to transfer listing to NASDAQ capital market
• Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters